Pablo Lee

649 total citations
21 papers, 432 citations indexed

About

Pablo Lee is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Pathology and Forensic Medicine. According to data from OpenAlex, Pablo Lee has authored 21 papers receiving a total of 432 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Oncology, 15 papers in Pulmonary and Respiratory Medicine and 3 papers in Pathology and Forensic Medicine. Recurrent topics in Pablo Lee's work include Lung Cancer Treatments and Mutations (15 papers), Lung Cancer Research Studies (10 papers) and Colorectal Cancer Treatments and Studies (5 papers). Pablo Lee is often cited by papers focused on Lung Cancer Treatments and Mutations (15 papers), Lung Cancer Research Studies (10 papers) and Colorectal Cancer Treatments and Studies (5 papers). Pablo Lee collaborates with scholars based in United States, Germany and Spain. Pablo Lee's co-authors include Alan Brnabic, Lisa M. Hess, Scott Barker, Natasha K. Stout, Amy Trentham‐Dietz, Oğuzhan Alagöz, Martin J. Yaffe, Anna N.A. Tosteson, Lisa Z. Scheifele and Joel S. Bader and has published in prestigious journals such as Journal of Clinical Oncology, Genetics and Journal of Thoracic Oncology.

In The Last Decade

Pablo Lee

21 papers receiving 425 citations

Peers

Countries citing papers authored by Pablo Lee

Since Specialization

Citations

This map shows the geographic impact of Pablo Lee's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Pablo Lee with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Pablo Lee more than expected).

Fields of papers citing papers by Pablo Lee

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Pablo Lee. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Pablo Lee. The network helps show where Pablo Lee may publish in the future.

Co-authorship network of co-authors of Pablo Lee

This figure shows the co-authorship network connecting the top 25 collaborators of Pablo Lee. A scholar is included among the top collaborators of Pablo Lee based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Pablo Lee. Pablo Lee is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Exploratory analysis of front-line therapies in REVEL: a randomised phase 3 study of ramucirumab plus docetaxel versus docetaxel for the treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy 2020 ·ESMO Open ·Edward B. Garon, Giorgio V. Scagliotti, Oliver Gautschi, Martin Reck, Michael Thomas, Lara Iglesias Docampo, Haralabos P. Kalofonos, Joo-Hang Kim, Steven Gans, (unknown), Sergey Orlov, Gebra Cuyún Carter, Annamaria H. Zimmermann, Ana B. Oton, Ekaterine Alexandris, Pablo Lee, Katharina Wolff, (unknown), Mark A. Socinski, M. Pérol	8
2	Relationship between Progression-free Survival and Overall Survival in Randomized Clinical Trials of Targeted and Biologic Agents in Oncology 2019 ·Journal of Cancer ·Lisa M. Hess, Alan Brnabic, (unknown), Pablo Lee, Scott Barker	56
3	Incidence and Management of Olaratumab Infusion-Related Reactions 2019 ·Journal of Oncology Practice ·Brian A. Van Tine, Rangaswamy Govindarajan, Steven Attia, Neeta Somaiah, Scott Barker, Ashwin Shahir, (unknown), Pablo Lee, Volker Wacheck, (unknown), William D. Tap	2
4	Exposure–response relationship for ramucirumab from the randomized, double-blind, phase 3 REVEL trial (docetaxel versus docetaxel plus ramucirumab) in second-line treatment of metastatic non-small cell lung cancer 2018 ·Cancer Chemotherapy and Pharmacology ·Egbert F. Smit, Edward B. Garon, Martin Reck, Federico Cappuzzo, Paolo Bidoli, Roger B. Cohen, Ling Gao, Lisa M. O’Brien, Pablo Lee, Annamaria H. Zimmermann, David Ferry, Allen S. Melemed, M. Pérol	15
5	Antiangiogenic therapy for patients with aggressive or refractory advanced non-small cell lung cancer in the second-line setting 2018 ·Lung Cancer ·Martin Reck, Marina Chiara Garassino, Martina Imbimbo, Frances A. Shepherd, Mark A. Socinski, Jin‐Yuan Shih, Anne S. Tsao, Pablo Lee, Katherine B. Winfree, Andreas Sashegyi, Rebecca Cheng, (unknown), Benjamin Levy, Edward B. Garon	23
6	Randomized, Double-Blind Phase Ib/III Study of Erlotinib With Ramucirumab or Placebo in Previously Untreated EGFR-Mutant Metastatic Non–Small-Cell Lung Cancer (RELAY): Phase Ib Results 2017 ·Clinical Lung Cancer ·Martin Reck, Edward B. Garon, Luis Paz‐Ares, Santiago Ponce, Jesús Corral Jaime, Óscar Juan, Ernest Nadal, Katsuyuki Kiura, Ryan C. Widau, (unknown), Rita P. Dalal, Pablo Lee, Kazuhiko Nakagawa	12
7	Efficacy and Safety of Ramucirumab With Docetaxel Versus Placebo With Docetaxel as Second-Line Treatment of Advanced Non–Small-Cell Lung Cancer: A Subgroup Analysis According to Patient Age in the REVEL Trial 2017 ·Clinical Lung Cancer ·Suresh S. Ramalingam, M. Pérol, Martin Reck, Rubén Dario Kowalyszyn, Oliver Gautschi, Martin Kimmich, Eun Kyung Cho, Grzegorz Czyżewicz, Alexandru Grigorescu, Nina Karaseva, Shaker R. Dakhil, Pablo Lee, (unknown), Andreas Sashegyi, Ekaterine Alexandris, Gebra Cuyún Carter, Katherine B. Winfree, Edward B. Garon	6
8	Treatment outcomes by histology in REVEL: A randomized phase III trial of Ramucirumab plus docetaxel for advanced non-small cell lung cancer 2017 ·Lung Cancer ·(unknown), M. Pérol, Tudor–Eliade Ciuleanu, Rubén Dario Kowalyszyn, Martin Reck, C. Lewanski, Konstantinos Syrigos, Óscar Arrieta, Kumar Prabhash, Keunchil Park, Joanna Pikiel, Tuncay Göksel, Pablo Lee, (unknown), Gebra Cuyún Carter, Ekaterine Alexandris, Edward B. Garon	13
9	Outcomes in patients with aggressive or refractory disease from REVEL: A randomized phase III study of docetaxel with ramucirumab or placebo for second-line treatment of stage IV non-small-cell lung cancer 2017 ·Lung Cancer ·Martin Reck, Luis Paz‐Ares, Paolo Bidoli, Federico Cappuzzo, Shaker R. Dakhil, Denis Moro‐Sibilot, Hossein Borghaei, Melissa L. Johnson, Robert M. Jotte, Nathan A. Pennell, Frances A. Shepherd, Anne S. Tsao, Michael Thomas, Gebra Cuyún Carter, (unknown), Ekaterine Alexandris, Pablo Lee, Annamaria H. Zimmermann, Andreas Sashegyi, M. Pérol	29
10	OA11.02 Randomized Phase 1b/3 Study of Erlotinib plus Ramucirumab in First-Line EGFR Mut + Stage IV NSCLC: Phase 1b Safety Results 2017 ·Journal of Thoracic Oncology ·Kazuhiko Nakagawa, Luis Paz‐Ares, Santiago Ponce, J. Corral, Óscar Juan, Ernest Nadal, Katsuyuki Kiura, Jingyi Liu, (unknown), Joseph Treat, Rita P. Dalal, Pablo Lee, Martin Reck	1
11	Treatment Rationale and Study Design for the RELAY Study: A Multicenter, Randomized, Double-Blind Study of Erlotinib With Ramucirumab or Placebo in Patients With Epidermal Growth Factor Receptor Mutation-Positive Metastatic Non–Small-Cell Lung Cancer 2016 ·Clinical Lung Cancer ·Edward B. Garon, Martin Reck, Luis Paz‐Ares, Santiago Ponce, Jesús Corral Jaime, Óscar Juan, Ernest Nadal, Pablo Lee, Rita P. Dalal, Jingyi Liu, (unknown), Joseph Treat, Kazuhiko Nakagawa	9
12	A randomized, double-blind, phase II study of ramucirumab plus docetaxel vs placebo plus docetaxel in Japanese patients with stage IV non-small cell lung cancer after disease progression on platinum-based therapy 2016 ·Lung Cancer ·Kiyotaka Yoh, Yukio Hosomi, Kazuo Kasahara, Kazuhiko Yamada, Toshiaki Takahashi, Nobuyuki Yamamoto, Makoto Nishio, Yuichiro Ohe, (unknown), Takashi Nakamura, Sotaro Enatsu, Pablo Lee, David Ferry, Tomohide Tamura, Kazuhiko Nakagawa	74
13	East Asian Subgroup Analysis of a Randomized, Double-Blind, Phase 3 Study of Docetaxel and Ramucirumab Versus Docetaxel and Placebo in the Treatment of Stage IV Non-small Cell Lung Cancer Following Disease Progression after One Prior Platinum-Based Therapy (REVEL) 2016 ·Cancer Research and Treatment ·Keunchil Park, Joo-Hang Kim, Eun Kyung Cho, Jin Hyoung Kang, Jin‐Yuan Shih, Annamaria H. Zimmermann, Pablo Lee, Ekaterine Alexandris, Tarun Puri, Mauro Orlando	16
14	Exploratory subgroup analysis of patients (Pts) refractory to first-line (1L) chemotherapy from REVEL, a randomized phase III study of docetaxel (DOC) with ramucirumab (RAM) or placebo (PBO) for second-line (2L) treatment of stage IV non-small-cell lung cancer (NSCLC). 2016 ·Journal of Clinical Oncology ·Martin Reck, Luis Paz‐Ares, Paolo Bidoli, Federico Cappuzzo, Shaker R. Dakhil, Denis Moro‐Sibilot, Hossein Borghaei, Melissa L. Johnson, Robert M. Jotte, Nathan A. Pennell, Frances A. Shepherd, Anne S. Tsao, Gebra Cuyún Carter, (unknown), Ekaterine Alexandris, Pablo Lee, Annamaria H. Zimmermann, Joseph Treat, Andreas Sashegyi, M. Pérol	3
15	Total cost-effectiveness of mammography screening strategies. 2015 ·PubMed ·Nicole Mittmann, Natasha K. Stout, Pablo Lee, Anna N.A. Tosteson, Amy Trentham‐Dietz, Oğuzhan Alagöz, Martin J. Yaffe	29
16	Modelling mammography screening for breast cancer in the Canadian context: Modification and testing of a microsimulation model. 2015 ·PubMed ·Martin J. Yaffe, Nicole Mittmann, Pablo Lee, Anna N.A. Tosteson, Amy Trentham‐Dietz, Oğuzhan Alagöz, Natasha K. Stout	10
17	Clinical outcomes of modelling mammography screening strategies. 2015 ·PubMed ·Martin J. Yaffe, Nicole Mittmann, Pablo Lee, Anna N.A. Tosteson, Amy Trentham‐Dietz, Oğuzhan Alagöz, Natasha K. Stout	17
18	A Phase II, Open-Label Study of Ramucirumab in Combination with Paclitaxel and Carboplatin as First-Line Therapy in Patients with Stage IIIB/IV Non–Small-Cell Lung Cancer 2014 ·Journal of Thoracic Oncology ·D. Ross Camidge, Eamon M. Berge, Robert C. Doebele, Marc Ballas, Thierry Jahan, Missak Haigentz, David Hoffman, James Spicer, Howard West, Pablo Lee, Yang Ling, Adarsh Joshi, Ling Gao, Sergey Yurasov, Alain C. Mita	41
19	Responsiveness of the Testing Morbidities Index in Colonoscopy 2013 ·Value in Health ·J. Shannon Swan, Chin Hur, Pablo Lee, (unknown), Karen Donelan	15
20	Teaching Synthetic Biology, Bioinformatics and Engineering to Undergraduates: The Interdisciplinary Build-a-Genome Course 2008 ·Genetics ·Jessica S. Dymond, Lisa Z. Scheifele, Sarah M. Richardson, Pablo Lee, Srinivasan Chandrasegaran, Joel S. Bader, Jef D. Boeke	47

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact